Palgesic Retard

Active Ingredient:: Tapentadol
Origin:: EU

Palgesic Retard (Tapentadol)

International sale not permitted. Listed for the domestic market and B2B only.

Tapentadol, the active ingredient in Palgesic Retard, is an opioid analgesic presented as a controlled‑release formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when alternative treatments are inadequate.
GNH India supplies Palgesic Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Kern Pharma, S.L.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Tapentadol is used in pain management pathways for several chronic pain conditions.

Chronic low back pain: provides sustained relief of moderate to severe pain over 24 hours.
Osteoarthritis pain: improves functional mobility by reducing pain intensity.
Neuropathic pain associated with diabetic peripheral neuropathy: lessens pain spikes and improves quality of life.

How It Works

Tapentadol exerts analgesia through a dual mechanism: it is a µ‑opioid receptor agonist that activates central opioid pathways and simultaneously inhibits the reuptake of norepinephrine, enhancing descending inhibitory pain signals. This combined action reduces the perception of pain without relying solely on opioid receptor activation.

Side Effects

Tapentadol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

Nausea: mild to moderate upset stomach.
Constipation: reduced bowel movements.
Dizziness: transient light‑headedness.
Headache: mild throbbing pain.
Somnolence: feeling unusually sleepy.
Dry mouth: reduced salivation.

Serious or Rare Side Effects

Respiratory depression: slowed breathing that may require medical attention.
Seizures: rare occurrence, especially at high doses or with interacting drugs.
Severe hypotension: sudden drop in blood pressure.
Allergic reactions: rash, itching, swelling, or anaphylaxis.
Dependence or abuse potential: risk of developing opioid use disorder.
adrenal insufficiency: rare hormonal imbalance affecting stress response.

Precautions & Warnings

When prescribing Tapentadol, clinicians should consider several safety measures to minimize risk.

Assess pain severity and prior opioid exposure: ensure suitability for opioid therapy.
Evaluate renal and hepatic function: adjust use in impairment.
Monitor for signs of respiratory depression: especially during dose escalation.
Counsel patients on constipation management: use laxatives or diet changes.
Advise against concurrent use with CNS depressants: increased sedation risk.
Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Tapentanol may interact with a variety of medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

MAO inhibitors: risk of hypertensive crisis.
CNS depressants (benzodiazepines, barbiturates): additive sedation and respiratory depression.
CYP2D6 inhibitors (paroxetine, fluoxetine): increased tapentadol plasma levels.

Moderate Interactions (Monitor Closely)

Serotonergic agents (tramadol, SSRIs, SNRIs): potential serotonin syndrome.
Antihistamines (diphenhydramine): enhanced drowsiness.
Alcohol: increased central nervous system depression.

Frequently Asked Questions

Palgesic Retard contains tapentadol, an opioid analgesic indicated for the management of moderate to severe chronic pain in adults, such as low‑back pain, osteoarthritis and certain neuropathic pain conditions when other treatments are insufficient.

Tapentadol provides analgesia through a dual mechanism: it activates µ‑opioid receptors in the central nervous system and blocks the reuptake of norepinephrine, which together enhance descending inhibitory pathways and lower the perception of pain.

Current evidence does not indicate a clear safety profile for tapetnal

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 11 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.